Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Casey Maguire
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Chameleon Biosciences, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Maguire is a consultant for and holds equity in Chameleon Biosciences, Inc., a private company developing an enveloped Adeno Associated Virus (AAV) vector platform for repeated dosing of systemic gene therapy. The research project involves testing different AAV vectors for gene delivery efficiency. The research and Chameleon Biosciences are both focused on developing AAV vector technology; therefore, the results of the research could be of interest to the company as they could increase/decrease interest in the company’s technology, and, if the research is successful, the company may have an interest in the resulting IP. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Enhanced gene delivery for CNS and sensory disorders
PROJECT NARRATIVE Hearing and balance disorders are a major threat to public health. No effective therapies exist to restore hearing in patients. Using a new gene delivery system technology developed in our laboratory, this proposal seeks to efficiently deliver therapeutic genes to the cells in the ear responsible for hearing and balance, which could provide an effective treatment for patients with hearing and balance disorders.
Filed on April 01, 2019.
Tell us what you know about Casey Maguire's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Casey Maguire”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Casey Maguire | Harvard Medical School | Conflict of Interest | Chameleon Biosciences, Inc. | Value cannot be readily determined |
| Casey Maguire | Massachusetts General Hospital | Conflict of Interest | Chameleon Biosciences, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.